Cytarabine
- Generic Name
- Cytarabine
- Brand Names
- Cytosar, Vyxeos
- Drug Type
- Small Molecule
- Chemical Formula
- C9H13N3O5
- CAS Number
- 147-94-4
- Unique Ingredient Identifier
- 04079A1RDZ
- Background
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
- Indication
For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.
Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia
- Associated Therapies
- -
Bortezomib and Chemotherapy in Treating Participants With Lymphoid Malignancies Undergoing Stem Cell Transplant
- Conditions
- CD20 PositiveHematopoietic and Lymphoid Cell NeoplasmLymphocytic NeoplasmLymphoma
- Interventions
- Procedure: Allogeneic Hematopoietic Stem Cell TransplantationBiological: Anti-Thymocyte GlobulinDrug: BortezomibDrug: CarmustineDrug: CytarabineDrug: EtoposideBiological: FilgrastimDrug: MelphalanDrug: MethotrexateBiological: RituximabDrug: Tacrolimus
- First Posted Date
- 2007-02-23
- Last Posted Date
- 2019-09-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT00439556
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia
- Conditions
- Leukemia
- Interventions
- Drug: asparaginaseDrug: cyclophosphamideDrug: cytarabineDrug: daunorubicin hydrochlorideDrug: dexamethasoneDrug: doxorubicin hydrochlorideDrug: ifosfamideDrug: etoposideDrug: mercaptopurineDrug: methotrexateDrug: prednisoneDrug: thioguanineDrug: vincristine sulfateDrug: vindesineRadiation: radiation therapy
- First Posted Date
- 2007-02-01
- Last Posted Date
- 2013-05-29
- Lead Sponsor
- University Hospital Schleswig-Holstein
- Target Recruit Count
- 4559
- Registration Number
- NCT00430118
- Locations
- 🇦🇹
LKH Leoben, Leoben, Austria
🇦🇹Landeskrankenhaus Feldkirch, Feldkirch-Tisis, Austria
🇦🇹Universitaet Kinderklinik, Graz, Austria
Research Study to Determine if an Experimental Agent, LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation
- Conditions
- Hematologic Malignancies
- Interventions
- Drug: L-leucyl-L-leucine Methyl Ester (LLME)Drug: FludarabineDrug: CytarabineDrug: CyclophosphamideDrug: TacrolimusDrug: MesnaBiological: Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF)Procedure: Hematopoietic stem cell transplantation (HSCT)
- First Posted Date
- 2007-01-31
- Last Posted Date
- 2016-11-29
- Target Recruit Count
- 14
- Registration Number
- NCT00429416
- Locations
- 🇺🇸
Thomas Jefferson University', Philadelphia, Pennsylvania, United States
Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease
- Conditions
- LeukemiaLymphomaMultiple Myeloma and Plasma Cell NeoplasmMyelodysplastic SyndromesPrecancerous ConditionSecondary Myelofibrosis
- First Posted Date
- 2007-01-18
- Last Posted Date
- 2016-02-29
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Registration Number
- NCT00423826
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Standard Idarubicin and Cytarabine for the Treatment of Acute Myeloid Leukemia (AML)
- Conditions
- LeukemiaAcute Myeloid LeukemiaAML
- Interventions
- First Posted Date
- 2007-01-17
- Last Posted Date
- 2018-08-23
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 175
- Registration Number
- NCT00422591
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukemia With Myelodysplasia-Related ChangesAdult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1Adult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2AUntreated Adult Acute Myeloid LeukemiaAdult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11Acute Myeloid Leukemia
- Interventions
- Procedure: Autologous Bone Marrow TransplantationProcedure: Autologous Hematopoietic Stem Cell TransplantationDrug: BusulfanDrug: CytarabineDrug: Daunorubicin HydrochlorideDrug: DecitabineDrug: EtoposideBiological: FilgrastimOther: Laboratory Biomarker AnalysisOther: Pharmacological Study
- First Posted Date
- 2006-12-28
- Last Posted Date
- 2019-02-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 546
- Registration Number
- NCT00416598
- Locations
- 🇺🇸
Northwell Health NCORP, Lake Success, New York, United States
🇺🇸Northwell Health/Center for Advanced Medicine, Lake Success, New York, United States
🇺🇸University of Illinois, Chicago, Illinois, United States
Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Primary CNS Lymphoma
- Conditions
- Brain and Central Nervous System TumorsLymphoma
- Interventions
- Biological: filgrastimBiological: rituximabDrug: cytarabineDrug: etoposide phosphateDrug: leucovorin calciumDrug: methotrexateDrug: temozolomide
- First Posted Date
- 2006-12-28
- Last Posted Date
- 2015-08-20
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 10
- Registration Number
- NCT00416819
Low-Dose Cytarabine in Treating Infants With Down Syndrome and Transient Myeloproliferative Disorder
- First Posted Date
- 2006-12-13
- Last Posted Date
- 2015-09-30
- Lead Sponsor
- Children's Oncology Group
- Registration Number
- NCT00411281
Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005)
- Conditions
- Acute Promyelocytic Leukemia
- First Posted Date
- 2006-12-06
- Last Posted Date
- 2014-10-28
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 300
- Registration Number
- NCT00408278
- Locations
- 🇪🇸
Hospital La Fe, Valencia, Spain
🇪🇸Hospital de Cruces, Santander, Spain
🇪🇸Hospital de Santiago de Compostela, Santiago de Compostela, Spain
Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
- Conditions
- Adult Acute Basophilic LeukemiaAdult Acute Megakaryoblastic Leukemia (M7)Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Erythroleukemia (M6a)Untreated Adult Acute Myeloid LeukemiaAdult Acute Eosinophilic LeukemiaAdult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Interventions
- First Posted Date
- 2006-12-05
- Last Posted Date
- 2015-08-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 45
- Registration Number
- NCT00407966
- Locations
- 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.